Eric Mayoux

6.2k total citations · 5 hit papers
51 papers, 5.0k citations indexed

About

Eric Mayoux is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Surgery. According to data from OpenAlex, Eric Mayoux has authored 51 papers receiving a total of 5.0k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Endocrinology, Diabetes and Metabolism, 28 papers in Molecular Biology and 21 papers in Surgery. Recurrent topics in Eric Mayoux's work include Diabetes Treatment and Management (32 papers), Pancreatic function and diabetes (21 papers) and Metabolism, Diabetes, and Cancer (13 papers). Eric Mayoux is often cited by papers focused on Diabetes Treatment and Management (32 papers), Pancreatic function and diabetes (21 papers) and Metabolism, Diabetes, and Cancer (13 papers). Eric Mayoux collaborates with scholars based in Germany, France and United States. Eric Mayoux's co-authors include Michael Mark, Ele Ferrannini, Volker Vallon, Hermann Koepsell, Scott C. Thomson, Takahiro Masuda, Timo Rieg, Maria Gerasimova, D. Charlemagne and Frédérique Scamps and has published in prestigious journals such as Journal of Biological Chemistry, PLoS ONE and Circulation Research.

In The Last Decade

Eric Mayoux

49 papers receiving 4.9k citations

Hit Papers

CV Protection in the EMPA... 2013 2026 2017 2021 2016 2017 2013 2018 2020 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
    2016 741 citations Michael Mark, Eric Mayoux et al. profile →
  2. SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice
    2017 402 citations Liang Xu, Naoto Nagata et al. EBioMedicine profile →
  3. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice
    2013 402 citations Volker Vallon, Eric Mayoux et al. profile →
  4. Empagliflozin Increases Cardiac Energy Production in Diabetes
    2018 293 citations Subodh Verma, Sonia Rawat et al. JACC Basic to Translational Science profile →
  5. SGLT2 Inhibition Mediates Protection from Diabetic Kidney Disease by Promoting Ketone Body-Induced mTORC1 Inhibition
    2020 267 citations Issei Tomita, Shinji Kume et al. Cell Metabolism profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Eric Mayoux 3.3k 2.1k 1.9k 1.4k 714 51 5.0k
Hirofumi Hitomi 1.4k 0.4× 942 0.5× 651 0.3× 1.2k 0.9× 666 0.9× 98 3.7k
Farhad Amiri 1.3k 0.4× 1.5k 0.7× 663 0.3× 1.6k 1.1× 1.1k 1.6× 45 4.2k
Marta Letizia Hribal 2.0k 0.6× 2.3k 1.1× 1.3k 0.7× 807 0.6× 1.3k 1.8× 124 5.7k
Anette Fiebeler 1.3k 0.4× 1.2k 0.6× 840 0.4× 1.5k 1.0× 411 0.6× 60 4.0k
Gláucia E. Callera 1.1k 0.3× 931 0.5× 679 0.4× 1.1k 0.8× 1.0k 1.5× 58 3.5k
Keiji Isshiki 1.1k 0.3× 1.7k 0.8× 593 0.3× 698 0.5× 898 1.3× 73 5.1k
Aurélie Nguyen Dinh Cat 1.2k 0.4× 788 0.4× 699 0.4× 975 0.7× 622 0.9× 42 2.9k
Christian G. Brilla 2.6k 0.8× 1.5k 0.7× 1.7k 0.9× 5.7k 4.1× 478 0.7× 63 7.7k
Claude Delcayre 2.1k 0.7× 1.5k 0.7× 1.3k 0.7× 2.2k 1.6× 254 0.4× 88 4.5k
David R. Powell 1.8k 0.6× 1.0k 0.5× 856 0.4× 382 0.3× 338 0.5× 39 2.6k

Countries citing papers authored by Eric Mayoux

Since Specialization
Citations

This map shows the geographic impact of Eric Mayoux's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric Mayoux with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric Mayoux more than expected).

Fields of papers citing papers by Eric Mayoux

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric Mayoux. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric Mayoux. The network helps show where Eric Mayoux may publish in the future.

Co-authorship network of co-authors of Eric Mayoux

This figure shows the co-authorship network connecting the top 25 collaborators of Eric Mayoux. A scholar is included among the top collaborators of Eric Mayoux based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric Mayoux. Eric Mayoux is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Park, Sin‐Hee, S. Gærtner, Hyun-Ho Lee, et al.. (2020). Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat. Cardiovascular Diabetology. 19(1). 19–19. 99 indexed citations
2.
Tomita, Issei, Shinji Kume, Sho Sugahara, et al.. (2020). SGLT2 Inhibition Mediates Protection from Diabetic Kidney Disease by Promoting Ketone Body-Induced mTORC1 Inhibition. Cell Metabolism. 32(3). 404–419.e6. 267 indexed citations breakdown →
3.
Idris-Khodja, Noureddine, Lamia Amoura, Malak Abbas, et al.. (2018). Upregulation of sodium-glucose cotransporter 2 (SGLT2) expression in cultured senescent endothelial cells and in arterial sites at risk in vivo in rats. Archives of Cardiovascular Diseases Supplements. 10(2). 224–224. 4 indexed citations
4.
Aroor, Annayya R., Nitin A. Das, Andrea J. Carpenter, et al.. (2018). Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury. Cardiovascular Diabetology. 17(1). 108–108. 135 indexed citations
5.
Verma, Subodh, Sonia Rawat, Kim L. Ho, et al.. (2018). Empagliflozin Increases Cardiac Energy Production in Diabetes. JACC Basic to Translational Science. 3(5). 575–587. 293 indexed citations breakdown →
6.
Abdurrachim, Desiree, et al.. (2017). The effect of a single dose of Empagliflozin on cardiac energy status in diabetic mice. Diabetes. 66. 1 indexed citations
7.
Habibi, Javad, Annayya R. Aroor, James R. Sowers, et al.. (2017). Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes. Cardiovascular Diabetology. 16(1). 9–9. 205 indexed citations
8.
Hammoudi, Nadjib, Dongtak Jeong, Rajvir Singh, et al.. (2017). Empagliflozin Improves Left Ventricular Diastolic Dysfunction in a Genetic Model of Type 2 Diabetes. Cardiovascular Drugs and Therapy. 31(3). 233–246. 121 indexed citations
9.
Xu, Liang, Naoto Nagata, Mayumi Nagashimada, et al.. (2017). SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice. EBioMedicine. 20. 137–149. 402 indexed citations breakdown →
10.
Chen, Lihua, et al.. (2016). The Effects of Empagliflozin, an SGLT2 Inhibitor, on Pancreatic β-Cell Mass and Glucose Homeostasis in Type 1 Diabetes. PLoS ONE. 11(1). e0147391–e0147391. 66 indexed citations
11.
Benetti, Elisa, Raffaella Mastrocola, Juan Carlos Cutrìn, et al.. (2016). Empagliflozin Protects against Diet-Induced NLRP-3 Inflammasome Activation and Lipid Accumulation. Journal of Pharmacology and Experimental Therapeutics. 359(1). 45–53. 79 indexed citations
12.
Michel, Martin C., Eric Mayoux, & Volker Vallon. (2015). A comprehensive review of the pharmacodynamics of the SGLT2 inhibitor empagliflozin in animals and humans. Naunyn-Schmiedeberg s Archives of Pharmacology. 388(8). 801–816. 54 indexed citations
13.
Kern, Matthias, Nora Klöting, Michael Mark, et al.. (2015). The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin. Metabolism. 65(2). 114–123. 101 indexed citations
14.
Hansen, Henrik H., Jacob Jelsing, Gitte Hansen, et al.. (2014). The Sodium Glucose Cotransporter Type 2 Inhibitor Empagliflozin Preserves β-Cell Mass and Restores Glucose Homeostasis in the Male Zucker Diabetic Fatty Rat. Journal of Pharmacology and Experimental Therapeutics. 350(3). 657–664. 51 indexed citations
15.
Oelze, Matthias, Swenja Kröller‐Schön, Philipp Welschof, et al.. (2014). The Sodium-Glucose Co-Transporter 2 Inhibitor Empagliflozin Improves Diabetes-Induced Vascular Dysfunction in the Streptozotocin Diabetes Rat Model by Interfering with Oxidative Stress and Glucotoxicity. PLoS ONE. 9(11). e112394–e112394. 260 indexed citations
16.
Mayoux, Eric. (2003). Alfuzosin Improves Penile Erection Triggered by Apomorphine in Spontaneous Hypertensive Rats. European Urology. 45(1). 110–116. 12 indexed citations
17.
Brusq, Jean‐Marie, et al.. (1999). Effects of C‐type natriuretic peptide on rat cardiac contractility. British Journal of Pharmacology. 128(1). 206–212. 55 indexed citations
18.
19.
Mansier, P., B Chevalier, Eric Mayoux, et al.. (1990). Membrane proteins of the myocytes in cardiac overload.. British Journal of Clinical Pharmacology. 30(S1). 43S–48S. 3 indexed citations
20.
Mayoux, Eric, et al.. (1988). Adaptational Process of the Cardiac Ca2+ Channels to Pressure Overload. Journal of Cardiovascular Pharmacology. 12(4). 390–396. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hirofumi Hitomi Breakdown of academic impact, for papers by Farhad Amiri Breakdown of academic impact, for papers by Marta Letizia Hribal Breakdown of academic impact, for papers by Anette Fiebeler Breakdown of academic impact, for papers by Gláucia E. Callera Breakdown of academic impact, for papers by Keiji Isshiki Breakdown of academic impact, for papers by Aurélie Nguyen Dinh Cat Breakdown of academic impact, for papers by Christian G. Brilla Breakdown of academic impact, for papers by Claude Delcayre Breakdown of academic impact, for papers by David R. Powell
Rankless by CCL
2026